Primary |
Chronic Myeloid Leukaemia |
66.3% |
Gastrointestinal Stromal Tumour |
5.9% |
Prophylaxis |
5.9% |
Acute Lymphocytic Leukaemia |
2.2% |
Chromosome Analysis Abnormal |
2.2% |
Graft Versus Host Disease |
1.8% |
Hypertension |
1.8% |
Myocardial Ischaemia |
1.8% |
Chronic Myeloid Leukaemia Transformation |
1.5% |
Prophylaxis Against Graft Versus Host Disease |
1.5% |
White Blood Cell Count Increased |
1.5% |
Acute Myeloid Leukaemia |
1.1% |
Diabetes Mellitus |
1.1% |
Urosepsis |
1.1% |
Arthralgia |
0.7% |
Blast Crisis In Myelogenous Leukaemia |
0.7% |
Blood Magnesium Decreased |
0.7% |
Blood Potassium Decreased |
0.7% |
Dermatomyositis |
0.7% |
Myelofibrosis |
0.7% |
|
Death |
14.4% |
Electrocardiogram Qt Prolonged |
14.4% |
White Blood Cell Count Increased |
7.8% |
Pyrexia |
6.7% |
Rash |
6.7% |
Pleural Effusion |
5.6% |
Maternal Exposure During Pregnancy |
4.4% |
Myocardial Infarction |
4.4% |
Drug Ineffective |
3.3% |
Drug Interaction |
3.3% |
Normal Newborn |
3.3% |
Pseudomonas Infection |
3.3% |
Second Primary Malignancy |
3.3% |
Vith Nerve Paralysis |
3.3% |
Vomiting |
3.3% |
White Blood Cell Count Decreased |
3.3% |
Blast Crisis In Myelogenous Leukaemia |
2.2% |
Cerebrovascular Accident |
2.2% |
Cholangitis Acute |
2.2% |
Completed Suicide |
2.2% |
|
Secondary |
Chronic Myeloid Leukaemia |
60.9% |
Acute Lymphocytic Leukaemia |
8.9% |
Prophylaxis |
4.9% |
Hypertension |
4.3% |
Gastrointestinal Stromal Tumour |
3.4% |
Diabetes Mellitus |
2.2% |
Chromosome Analysis Abnormal |
1.8% |
Hypothyroidism |
1.5% |
Atrial Fibrillation |
1.2% |
Graft Versus Host Disease |
1.2% |
Nasopharyngitis |
1.2% |
Prophylaxis Against Graft Versus Host Disease |
1.2% |
White Blood Cell Count Increased |
1.2% |
Benign Prostatic Hyperplasia |
0.9% |
Blast Crisis In Myelogenous Leukaemia |
0.9% |
Product Used For Unknown Indication |
0.9% |
Relapsing Fever |
0.9% |
Thyroid Disorder |
0.9% |
Acute Lymphocytic Leukaemia Recurrent |
0.6% |
Asthma |
0.6% |
|
Thrombocytopenia |
13.5% |
Electrocardiogram Qt Prolonged |
8.1% |
White Blood Cell Count Decreased |
8.1% |
Drug Resistance |
6.8% |
Peripheral Arterial Occlusive Disease |
6.8% |
Death |
5.4% |
Metrorrhagia |
5.4% |
Myocardial Infarction |
5.4% |
Pleural Effusion |
5.4% |
Neoplasm Malignant |
4.1% |
Non-small Cell Lung Cancer |
4.1% |
Pseudomonas Infection |
4.1% |
White Blood Cell Count Increased |
4.1% |
Blood Glucose Increased |
2.7% |
Cholestasis |
2.7% |
Completed Suicide |
2.7% |
Dengue Fever |
2.7% |
Drug Administration Error |
2.7% |
Drug Interaction |
2.7% |
Erythema |
2.7% |
|
Concomitant |
Chronic Myeloid Leukaemia |
26.2% |
Product Used For Unknown Indication |
18.4% |
Chronic Graft Versus Host Disease |
8.7% |
Prophylaxis |
6.8% |
Infection Prophylaxis |
5.8% |
Acute Graft Versus Host Disease |
4.9% |
Acute Lymphocytic Leukaemia |
4.9% |
Acute Lymphocytic Leukaemia Recurrent |
3.9% |
Antibiotic Therapy |
2.9% |
B Precursor Type Acute Leukaemia |
1.9% |
Gastric Ulcer |
1.9% |
Gastrointestinal Stromal Tumour |
1.9% |
Nausea |
1.9% |
Pain |
1.9% |
Premedication |
1.9% |
Vomiting |
1.9% |
Acute Myeloid Leukaemia |
1.0% |
Antiviral Treatment |
1.0% |
Blood Uric Acid |
1.0% |
Bone Marrow Failure |
1.0% |
|
Tachycardia |
11.1% |
Blood Creatinine Increased |
7.4% |
Renal Failure Acute |
7.4% |
Renal Failure Chronic |
7.4% |
Skin Disorder |
7.4% |
Thrombocytopenia |
7.4% |
Acute Lymphocytic Leukaemia |
3.7% |
Blast Cell Crisis |
3.7% |
Chronic Myeloid Leukaemia |
3.7% |
Death |
3.7% |
Febrile Bone Marrow Aplasia |
3.7% |
Leukocytosis |
3.7% |
Lung Neoplasm Malignant |
3.7% |
Myocardial Infarction |
3.7% |
Neurotoxicity |
3.7% |
Oedema |
3.7% |
Organising Pneumonia |
3.7% |
Pain |
3.7% |
Productive Cough |
3.7% |
Renal Vasculitis |
3.7% |
|
Interacting |
Product Used For Unknown Indication |
40.0% |
Hiv Infection |
30.0% |
Chronic Myeloid Leukaemia |
20.0% |
Tuberculosis |
10.0% |
|
Fluid Retention |
50.0% |
Cardiac Failure |
16.7% |
Drug Interaction |
16.7% |
Tuberculosis |
16.7% |
|